ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: We have previously shown that ENU can be used in CML cell lines to generate ABL-kinase mutations that can be selected in vitro by TKI and allows in vitro production of clinically relevant mutations such as T315I substitution [45].